Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

201147: a Phase IIIb, Randomized, Open-label Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen Compared With Continuation of the Current Antiretroviral Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed, The STRIIVING Study.

Next Previous
X
Search
Trial Profile

201147: a Phase IIIb, Randomized, Open-label Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen Compared With Continuation of the Current Antiretroviral Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed, The STRIIVING Study.

Status: Completed
Phase of Trial: Phase III/IV

Latest Information Update: 02 Nov 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abacavir/dolutegravir/lamivudine (Primary) ; Antiretrovirals; Atazanavir; Elvitegravir; Raltegravir
  • Indications HIV-1 infections
  • Focus Registrational; Therapeutic Use
  • Acronyms STRIIVING
  • Sponsors GlaxoSmithKline; ViiV Healthcare

    • Most Recent Events

    • 07 Mar 2019 Results assessing associated with HOMA-IR (homeostasis model of assessment -insulin resistance) and effect of dolutegravir over time from SPRING-1, STRIIVING, SWORD-1 and -2 trials presented at the 26th Conference on Retroviruses and Opportunistic Infections
    • 25 Feb 2016 Results presented at the 23rd Conference on Retroviruses and Opportunistic Infections
    • 24 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top